Abstract：Objective: The aim of study was to evaluate whether the 18F-FDG and 18F-fluoroacetate(18F-FAC) could be used to distinguish the different metastatic potential of hepatocellular carcinoma(HCC) models. Methods: Human HCC cell lines HepG2 and QGY7701 were cultured and implanted into nude mice to create HCC models. In vitro cell invasion assay was performed to judge invasion ability. Uptakes of 18F-FDG, 18F-FAC in two cells were assessed by in vitro uptake assay. In vivo imaging of tumor-bearing mice were obtained by animal PET/CT after injection of each tracer. ROI(region of interest) was drawn over tumor and lung to calculate T/NT(tumor/non-tumor). Results: The invasion ability of HepG2 was much higher than QGY7701(P<0.05), and the uptake ratio of 18F-FDG and 18F-FAC in HepG2 was higher than that in QGY7701(P<0.05) in vitro uptake assay. The 18F-FDG uptake of cells correlated with invasion capability(r=0.657, P<0.05). Meanwhile, in Micro-PET/CT study, the uptake of 18F-FDG and 18F-FAC in HepG2 tumor was higher than that in QGY7701 tumor(P<0.05). Conclusion: High uptake of 18F-FDG reflects higher invasion ability of HCC cell. Meanwhile, there is differentiation between two HCC models in 18F-FDG Micro-PET imaging. It indicates that 18F-FDG PET imaging could help to predict metastasis ability of HCC.
何婷婷1，王 卉1，徐白萱2，刘 健2，张小军2，田嘉禾2. 不同侵袭转移特性肝癌模型的18F-FDG和2-18F-乙酸盐联合显像[J]. 中国临床医学影像杂志, 2016, 27(4): 267-270.
HE Ting-ting1, WANG Hui1, XU Bai-xuan2, LIU Jian2, ZHANG Xiao-jun2, TIAN Jia-he2. Binding 18F-FDG and 18F-fluoroacetate Micro-PET imaging in human HCC model. JOURNAL OF CHINA MEDICAL IMAGING, 2016, 27(4): 267-270.
[1]Higashi T, Hatano E, Ikai I, et al. FDG PET as a prognostic predictor in the early post-therapeutic evaluation for unresectable hepatocellular carcinoma[J]. Eur J Nucl Med Mol Imaging, 2010, 37(3): 468-482.
[2]Salem N, Kuang Y, Wang F, et al. PET imaging of hepatocellular carcinoma with 2-deoxy-2[18F]fluoro-D-glucose, 6-deoxy-6[18F]fluoro-D-glucose, [1-11C]-acetate and [N-methyl-11C]-choline[J]. Q J Nucl Med Mol Imaging, 2009, 53(2): 144-156.
[3]Kim YK, Lee KW, Cho SY, et al. Usefulness 18F-FDG positron emission tomography/computed tomography for detecting recurrence of hepatocellular carcinoma in posttransplant patients[J]. Liver Transpl, 2010, 16(6): 767-772.
[4]张锦明，田嘉禾，姚树林，等. FDG模块自动化合成2-18F-乙酸盐及其临床前研究[J]. 中华核医学杂志，2007，27（4）：215-217.
[5]Lindhe O, Sun A, Ulin J, et al. [(18)F]Fluoroacetate is not a functional analogue of [(11)C]acetate in normal physiology[J]. Eur J Nucl Med Mol Imaging, 2009, 36(9): 1453-1459.
[6]Matthies A, Ezziddin S, Ulrich EM, et al. Imaging of prostate cancer metastases with 18F-fluoroacetate using PET/CT[J]. Eur J Nucl Med Mol Imaging, 2004, 31(5): 797.
[7]Ponde DE, Dence CS, Oyama N, et al. 18F-fluoroacetate: a potential acetate analog for prostate tumor imaging—in vivo evaluation of 18F-fluoroacetate versus 11C-acetate[J]. J Nucl Med， 2007, 48(3): 420-428.
[8]Ho CL, Yu SC, Yeung DW. 11C-acetate PET imaging in hepatocellular carcinoma and other liver masses[J]. J Nucl Med， 2003, 44(2): 213-221.
[9]Ho CL, Chen S, Yeung DW, et al. Dual-tracer PET/CT imaging in evaluation of metastatic hepatocellular carcinoma[J]. J Nucl Med， 2007, 8(6): 902-909.
